Pfizer DMD Gene Therapy Phase III Trial Faces A US Delay; Can Sarepta Close The Gap?
Sarepta Hopes To Meet With FDA Midyear
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.
